Literature DB >> 19438394

Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Joshua D Hartzell1, Robert Neff, Julie Ake, Robin Howard, Stephen Olson, Kristopher Paolino, Mark Vishnepolsky, Amy Weintrob, Glenn Wortmann.   

Abstract

The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19438394     DOI： 10.1086/599225

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  113 in total

1.  Colistin dosing and nephrotoxicity in a large community teaching hospital.

Authors:  C Andrew Deryke; Amanda J Crawford; Nizam Uddin; Mark R Wallace
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes.

Authors:  Bo Yun; Mohammad A K Azad; Cameron J Nowell; Roger L Nation; Philip E Thompson; Kade D Roberts; Tony Velkov; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children.

Authors:  Meltem Polat; Soner Sertan Kara; Anıl Tapısız; Hasan Tezer; Gökhan Kalkan; Anıl Dolgun
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

4.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

Review 5.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

6.  Variables determining the development of colistin-associated renal impairment.

Authors:  Bahadır Ceylan; Müdür Taniş; Muhammed Emin Akkoyunlu; Ahmet Çınar; Ayşe Ruhkar Kurt; Yasemin Akkoyunlu; Didem Ozkan; Hatice Kutbay Ozcelik; Turan Aslan; Muzaffer Fincancı; Şule Vatansever; Kadir İdin; Emine Guler; Harun Uysal
Journal:  Wien Klin Wochenschr       Date:  2015-04-28       Impact factor: 1.704

7.  Attributable Risk and Time Course of Colistin-Associated Acute Kidney Injury.

Authors:  Todd A Miano; Ebbing Lautenbach; F Perry Wilson; Wensheng Guo; Yuliya Borovskiy; Sean Hennessy
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 8.237

8.  Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium.

Authors:  Moataz M Hassan; Zied Gaifer; Ibrahim S Al-Zakwani
Journal:  Int J Clin Pharm       Date:  2018-03-14

9.  Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.

Authors:  Kade D Roberts; Mohammad A K Azad; Jiping Wang; Andrew S Horne; Philip E Thompson; Roger L Nation; Tony Velkov; Jian Li
Journal:  ACS Infect Dis       Date:  2015-09-04       Impact factor: 5.084

10.  A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes.

Authors:  Tony Velkov; Bo Yun; Elena K Schneider; Mohammad A K Azad; Olan Dolezal; Faye C Morris; Roger L Nation; Jiping Wang; Ke Chen; Heidi H Yu; Lv Wang; Philip E Thompson; Kade D Roberts; Jian Li
Journal:  ACS Infect Dis       Date:  2016-03-29       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.